Literature DB >> 12746847

Anti-androgenic action by red clover-derived dietary isoflavones reduces non-malignant prostate enlargement in aromatase knockout (ArKo) mice.

Renea A Jarred1, Stephen J McPherson, Margaret E E Jones, Evan R Simpson, Gail P Risbridger.   

Abstract

BACKGROUND: Red clover (RC)-derived dietary isoflavones have been implicated as potential preventative agents for the development and prevalence of non-malignant prostate diseases. This study investigated whether dietary isoflavones inhibit prostate growth in vivo in the aromatase knock-out (ArKO) mouse that exhibits lifelong elevation of androgens leading to prostate enlargement.
METHODS: Adult (11-week-old) wild-type (WT) and ArKO mice were fed on protein matched isoflavones free (IF) and RC (isoflavone rich) diets for 28 days. Individual prostate lobes and testes were weighed and collected for histological analysis and serum androgens were measured. Responses were compared to castration and estrogen administration to ArKO mice to determine the mechanism of action.
RESULTS: ArKO mice fed on IF diet exhibited enlarged prostate lobes and elevated serum androgens compared to WT mice. Following 28 days of RC diet, ArKO VP, AP, and SV weights were reduced to WT weights, although testis and body weights remained unaltered. Stereological analysis of VPs revealed a reduction in all components of the tissue, particularly the lumen. The RC diet reduced ArKO serum testosterone and dihydrotestosterone to WT levels. In comparison to castration and estrogen administration, the dietary isoflavones were shown to be anti-androgenic rather than weakly estrogenic, mimicking responses observed in the castrated ArKO, rather than estrogen treated ArKOs.
CONCLUSIONS: This study demonstrates that RC-derived isoflavones have a significant effect on prostatic growth, and are capable of reducing the enlarged non-malignant prostate phenotype of the adult ArKO mouse, by acting as anti-androgenic agents rather than weak estrogenic substances. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12746847     DOI: 10.1002/pros.10230

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  3 in total

1.  Estrogen signaling is not required for prostatic bud patterning or for its disruption by 2,3,7,8-tetrachlorodibenzo-p-dioxin.

Authors:  Sarah Hicks Allgeier; Chad M Vezina; Tien-Min Lin; Robert W Moore; Allen E Silverstone; Motoko Mukai; Jerrie Gavalchin; Paul S Cooke; Richard E Peterson
Journal:  Toxicol Appl Pharmacol       Date:  2009-06-10       Impact factor: 4.219

Review 2.  Pharmacological Effects and Potential Clinical Usefulness of Polyphenols in Benign Prostatic Hyperplasia.

Authors:  Kensuke Mitsunari; Yasuyoshi Miyata; Tomohiro Matsuo; Yuta Mukae; Asato Otsubo; Junki Harada; Tsubasa Kondo; Tsuyoshi Matsuda; Kojiro Ohba; Hideki Sakai
Journal:  Molecules       Date:  2021-01-16       Impact factor: 4.411

3.  The Effect of Seoritae Extract in Men with Mild to Moderate Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia.

Authors:  Woong Jin Bae; Hyo Jung Park; Hye Cheong Koo; Do Ram Kim; U-Syn Ha; Kang Sup Kim; Su Jin Kim; Hyuk Jin Cho; Sung Hoo Hong; Ji Youl Lee; Sung Yeoun Hwang; Sae Woong Kim
Journal:  Evid Based Complement Alternat Med       Date:  2016-06-13       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.